Qin Zhu

Array ( [id] => 19249168 [patent_doc_number] => 20240200155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => METHODS OF USING TOMATO BROWN RUGOSE FRUIT VIRUS AS AN INDICATOR OF FECAL STRENGTH AND CONTAMINATION, AND AS A CONTROL FOR VIRAL RNA EXTRACTION FROM STOOL [patent_app_type] => utility [patent_app_number] => 18/540291 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19098082 [patent_doc_number] => 20240117310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => Human Cross-Presenting CD141+CLEC9A+ Dendritic Cells, Methods of Producing the Same from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells and Methods of Use [patent_app_type] => utility [patent_app_number] => 18/468526 [patent_app_country] => US [patent_app_date] => 2023-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18831132 [patent_doc_number] => 20230399657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => LIVER DE-TARGETED RECOMBINANT AAV CAPSID PROTEINS [patent_app_type] => utility [patent_app_number] => 18/319052 [patent_app_country] => US [patent_app_date] => 2023-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18319052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656174 [patent_doc_number] => 20230302053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY [patent_app_type] => utility [patent_app_number] => 18/181135 [patent_app_country] => US [patent_app_date] => 2023-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612345 [patent_doc_number] => 20230279077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => ANTI-GLYCOPROTEIN D ANTIBODIES, METHODS OF PREPARATION, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/159473 [patent_app_country] => US [patent_app_date] => 2023-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612363 [patent_doc_number] => 20230279095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18 [patent_app_type] => utility [patent_app_number] => 18/068215 [patent_app_country] => US [patent_app_date] => 2022-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449627 [patent_doc_number] => 20230190903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => PROSTATE CANCER VACCINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/080634 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626742 [patent_doc_number] => 20230285548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES [patent_app_type] => utility [patent_app_number] => 18/080639 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649455 [patent_doc_number] => 20230295268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => COMPOSITIONS AND METHODS TO MANUFACTURE TUMOR SUPPRESSOR FUSIONS [patent_app_type] => utility [patent_app_number] => 17/953117 [patent_app_country] => US [patent_app_date] => 2022-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17953117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050971 [patent_doc_number] => 20240092940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => TREATMENT OF NECROTIZING ENTEROCOLITIS WITH SEMISYNTHETIC POLYCLONAL HUMAN SECRETORY IMMUNOGLOBIN A [patent_app_type] => utility [patent_app_number] => 17/949398 [patent_app_country] => US [patent_app_date] => 2022-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17949398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340191 [patent_doc_number] => 20230132140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => METHOD OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/945468 [patent_app_country] => US [patent_app_date] => 2022-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17945468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058396 [patent_doc_number] => 20220389482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => PRETREATMENT METHOD, PRETREATMENT SOLUTION, AND KIT FOR DETECTING NUCLEIC ACID OF VIRUS, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/891404 [patent_app_country] => US [patent_app_date] => 2022-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17891404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800530 [patent_doc_number] => 20250066455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NEUTRALISING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/293451 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18293451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597263 [patent_doc_number] => 20230272058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => COMPOSITIONS AND METHODS FOR PREVENTING ACUTE KIDNEY INJURY-INDUCED ACUTE LUNG INJURY (AKI-ALI) [patent_app_type] => utility [patent_app_number] => 17/858065 [patent_app_country] => US [patent_app_date] => 2022-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20335361 [patent_doc_number] => 20250339481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => METHOD OF DELIVERY OF FUSOGENIC ONCOLYTIC VIRUS AND THERAPEUTIC MOLECULES [patent_app_type] => utility [patent_app_number] => 18/289204 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19113102 [patent_doc_number] => 20240124852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/554972 [patent_app_country] => US [patent_app_date] => 2022-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19818092 [patent_doc_number] => 20250076299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => METHOD FOR REVALUATING ANTIBODY-DEPENDENT ENHANCEMENT REACTION USING PSEUDOVIRUS [patent_app_type] => utility [patent_app_number] => 18/520251 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18520251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172789 [patent_doc_number] => 20240158763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => OPTIMAL PRODUCTION OF SARS-COV-2 VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN MAMMALIAN CELLS [patent_app_type] => utility [patent_app_number] => 18/552762 [patent_app_country] => US [patent_app_date] => 2022-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170970 [patent_doc_number] => 20240156944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => ATTENUATED REOVIRUS-BASED VACCINE COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/283363 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111304 [patent_doc_number] => 20240123054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => CORONAVIRUS ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO [patent_app_type] => utility [patent_app_number] => 18/277536 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277536 [rel_patent_id] =>[rel_patent_doc_number] =>)